[
  {
    "ts": "2025-09-08T15:00:00+00:00",
    "headline": "First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity",
    "summary": "PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable safety profi",
    "url": "https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "bcb58933-00b4-3e03-9b80-235733698c5b",
      "content": {
        "id": "bcb58933-00b4-3e03-9b80-235733698c5b",
        "contentType": "STORY",
        "title": "First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity",
        "description": "",
        "summary": "PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable safety profi",
        "pubDate": "2025-09-08T15:00:00Z",
        "displayTime": "2025-09-08T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/823794cd8a992e0c9057cc4e398068ea",
          "originalWidth": 2729,
          "originalHeight": 301,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MPOVuOh.H98UgzPtOJaaJQ--~B/aD0zMDE7dz0yNzI5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/823794cd8a992e0c9057cc4e398068ea.cf.webp",
              "width": 2729,
              "height": 301,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U4jZH8130GTNmqbas7Tshg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/823794cd8a992e0c9057cc4e398068ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-08T13:42:00+00:00",
    "headline": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
    "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
    "url": "https://finance.yahoo.com/news/investing-oncology-3-cancer-stocks-134200392.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8ac85035-5f9a-37de-8b29-9f68151461d3",
      "content": {
        "id": "8ac85035-5f9a-37de-8b29-9f68151461d3",
        "contentType": "STORY",
        "title": "Investing in Oncology: 3 Cancer Stocks With Promising Pipelines",
        "description": "",
        "summary": "Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.",
        "pubDate": "2025-09-08T13:42:00Z",
        "displayTime": "2025-09-08T13:42:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhUbp770QgvNMyXdM9XKnA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ii2rwaxi8Dao2zrk4I.W2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investing-oncology-3-cancer-stocks-134200392.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investing-oncology-3-cancer-stocks-134200392.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]